<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Immunologic assays have been instrumental in implicating the Epstein-Barr virus (EBV) as an etiologic factor in nasopharyngeal <z:mp ids='MP_0002038'>carcinoma</z:mp> (NPC) and Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>In this report, the importance of a variety of specific assays to detect EBV in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> biopsies and antibodies to EBV antigens in serum from patients with NPC and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> is reviewed </plain></SENT>
<SENT sid="2" pm="."><plain>In both NPC and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>, the involvement of EBV appears to differ in various geographic locations </plain></SENT>
<SENT sid="3" pm="."><plain>Therefore, it is necessary to be able to interpret the available immunologic laboratory tests to know if a specific patient has "EBV-associated" or "non-EBV-associated" <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Such information is not only relevant to etiologic studies in different populations but to identifying individuals at high risk for NPC and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>, to monitoring their response to therapy, and to determining the most appropriate forms of therapy </plain></SENT>
</text></document>